1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

  • December 2016
  • 356 pages
  • GlobalData
Report ID: 3161486

Summary

Table of Contents

Search Inside

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

Summary

Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching sales of $29.2B by 2025. The US is the largest market for dyslipidemia therapies, contributing approximately 61.5% of total sales in the base year. GlobalData expects uptake of the revolutionary class of PCSK9 targeting biologics to be the strongest driver of growth in the dyslipidemia market in the 7MM, reaching peak sales of $9.5B in 2025.

Major drivers of Dyslipidemia market growth over the forecast period are -
- The launches of three PCSK9 inhibitors-Amgen’s Repatha, Sanofi and Regeneron’s Praluent, and Eli Lilly’s LY3015014-which will significantly boost market growth.
- The launch of several add-on therapies, including Esperion Therapeutic’s ETC-1002 and Merck and Amgen’s cholesteryl ester transfer protein (CETP) inhibitors
- Increase in global prevalence of dyslipidemia, coupled with growing awareness of the disease.

Although the dyslipidemia market has numerous well-established therapies and the pipeline is promising, there is a considerable level of unmet need. Patient compliance, cost-effective therapies, and drugs targeting rare diseases represent major unmet needs in the dyslipidemia space. Patient compliance remains the biggest issue, and a major contributing factor to this is the asymptomatic nature of this disease, as well as the burden of taking several pills daily to treat this disease.

In addition to this, many patients discontinue therapy, which puts them at considerable risk of experiencing a CV event. The PCSK9 monoclonal antibodies (mAbs), Repatha and Praluent, are expected to address the compliance issue due to their less frequent dosing schedules; however, KOLs indicated that patient education and enhanced disease awareness are important issues that also need to be addressed. While patient education is not a common area of focus for pharmaceutical companies, it’s clear that if diagnosis rates and patient compliance were increased, then this would translate to a boost in drug use and sales.

Companies reviewed in this report: Abbvie, Aegerion Pharmaceuticals Inc., Akcea Therapeutics Inc., Amarin, Amgen, AstraZeneca, Cerenis Therapeutics Inc., Daiichi Sankyo, Eli Lilly, Esperion Therapeutics Inc., Genzyme, Ionis Pharmaceuticals, Merck & Co., Regeneron Pharmaceuticals Inc., Sanofi, The Medicine Company.

Scope
- Overview of dyslipidemia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized dyslipidemia therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the dyslipidemia therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the dyslipidemia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the dyslipidemia therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the 7MM dyslipidemia therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Dyslipidemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Dyslipidemia Drugs Market 2017-2021

  • $ 3500
  • Industry report
  • March 2017
  • by Infiniti Research Limited

About Dyslipidemia Drugs Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia ...

Global Peripheral Arterial Disease (PAD) Therapeutics - Pharmaceuticals

  • $ 4950
  • Industry report
  • January 2017
  • by Global Industry Analysts

This report analyzes the worldwide markets for Peripheral Arterial Disease (PAD) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.